Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/1998

01-09-1998

c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value

Authors: Rafael Molina, Judith Jo, Xavier Filella, Gabriel Zanon, Jaume Pahisa, Montserrat Muñoz, Blanca Farrus, Maria Luz Latre, Carmen Escriche, Jordi Estape, Antonio M. Ballesta

Published in: Breast Cancer Research and Treatment | Issue 2/1998

Login to get access
Metadata
Title
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value
Authors
Rafael Molina
Judith Jo
Xavier Filella
Gabriel Zanon
Jaume Pahisa
Montserrat Muñoz
Blanca Farrus
Maria Luz Latre
Carmen Escriche
Jordi Estape
Antonio M. Ballesta
Publication date
01-09-1998
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/1998
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1005734429304

Other articles of this Issue 2/1998

Breast Cancer Research and Treatment 2/1998 Go to the issue

OriginalPaper

Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells

OriginalPaper

Suspected spinal cord compression in breast cancer patients: A multidisciplinary risk assessment

OriginalPaper

Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study

OriginalPaper

Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro

OriginalPaper

Letter to the editor

OriginalPaper

Adrenal androgens and human breast cancer: A new appraisal
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits